background image

Paid Clinical Trials Bethesda

Discover 2,408 paid clinical trials in Bethesda, Maryland. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter
2
FeaturedActive & Responsive

A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251

for
Geographic Atrophy
Location: Baltimore MD, Philadelphia PA, Lynchburg VA, Durham NC,
Sponsor: Genentech, Inc.

Sex: All

Age: 50+

Code: NCT05626114

Phase2, Recruiting
Featured

A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

for
Moderately to Severely Active Crohns Disease
Location: Chevy Chase MD, Baltimore MD, Richmond VA,
Sponsor: Hoffmann-La Roche

Sex: All

Age: 16 - 70+

Code: NCT06819891

Phase3, Recruiting
Featured

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

for
Metastatic Breast Cancer
Location: Washington D.C. DC, Hyattsville MD, Charlotte NC,
Sponsor: Hoffmann-La Roche

Sex: All

Age: 18+

Code: NCT05894239

Phase3, Recruiting
Featured

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

for
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer,
Location: Washington D.C. DC, Fairfax VA, Annapolis MD,
Sponsor: Hoffmann-La Roche

Sex: All

Age: 18+

Code: NCT06065748

Phase3, Recruiting
Featured

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

for
Obesity or Overweight, Type 2 Diabetes Mellitus
Location: Washington D.C. DC, Columbia MD, Manassas VA,
Sponsor: Hoffmann-La Roche

Sex: All

Age: 18+

Code: NCT07351058

Phase3, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image
Featured

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

for
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis,
Location: Greenbelt MD, Glen Burnie MD, Baltimore MD, Richmond VA,
Sponsor: 89bio, Inc.

Sex: All

Age: 18 - 70+

Code: NCT06318169

Phase3, Recruiting
Featured

A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

for
Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis,
Location: Greenbelt MD, Glen Burnie MD, Baltimore MD, Richmond VA,
Sponsor: 89bio, Inc.

Sex: All

Age: 18 - 70+

Code: NCT06419374

Phase3, Recruiting
Featured

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

for
Breast Cancer
Location: Annapolis MD, Hershey PA, Philadelphia PA, Norfolk VA,
Sponsor: Genentech, Inc.

Sex: All

Age: 18+

Code: NCT07100106

Phase1, Phase2, Recruiting
Featured

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

for
Breast Cancer
Location: Annapolis MD, Baltimore MD, East Brunswick NJ,
Sponsor: Hoffmann-La Roche

Sex: All

Age: 18+

Code: NCT06790693

Phase3, Recruiting
Featured

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

for
Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
Location: Baltimore MD, West Reading PA, Bethlehem PA, Norfolk VA,
Sponsor: Hoffmann-La Roche

Sex: All

Age: 18+

Code: NCT06793215

Phase3, Recruiting